



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/980,649	06/04/2002	Pierre Belhumeur	1051-1-019	6750
7590 Klauber & Jackson 411 Hackensack Avenue Hackensack, NJ 07601			EXAMINER KIM, TAEYOON	
			ART UNIT 1651	PAPER NUMBER
			MAIL DATE 05/28/2008	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

09/980,649

Applicant(s)

BELHUMEUR ET AL.

Examiner

Taeyoon Kim

Art Unit

1651

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 29 February 2008.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 3 and 5-15 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 3 and 5-15 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SF/88)
- Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
- Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

Claims 3 and 5-15 are pending.

Response to Amendment

Applicant's amendment and response filed on 2/29/2008 has been received and entered into the case.

Claims 1, 2 and 4 have been canceled, and claims 3 and 5-15 are pending and have been considered on the merits. All arguments have been fully considered.

The claim objections have been withdrawn due to the amendment.

The claim rejections under 35 U.S.C. §112 have been withdrawn due to the amendment.

In the response to the previous office action, applicant mainly argued that Safar et al. merely teach that heat or chemical treatment can have an effect on the degradation of a prion protein and the level of degradation can be measured by Western blot analysis, and Safar et al. do not teach or suggest a method of evaluating the efficiency of a sterilization process using proteins described by Coustou et al., Glover et al., or Wickner.

This argument is not persuasive. The method of Safar et al. teach steps of subjecting prion protein in a container to a sterilization process (temperature and/or chemical treatment), and determination of the level of degradation/inactivation of the prion protein measured by Western blotting analysis. These two steps are identical to the steps claimed in the current invention. The combination of Safar et al. with secondary references such as Coustou et al., Glover et al., or Wickner is based on the

analysis that Het-s, Sup35p, or Ure2p taught by prion taught by Coustou et al., Glover et al., or Wickner, respectively, is considered as an art-recognized equivalent to the prion protein taught by Safar et al. because these yeast prion proteins are known as prion analog possessing the same property as a mammalian counterpart.

Furthermore, applicant's attention is directed to *KSR v. Teleflex Inc.* (see M.P.E.P. §2141). M.P.E.P. §2141 states that so-called TSM (teaching-suggestion-motivation) test is one of several rationales to determine obviousness under 35 U.S.C. §103. However, this is not the only rationale to be used for determination of obviousness rejection. One of such rationales is (B) Simple substitution of one known element for another to obtain predictable results. This substitution of one known element for another is the rationale for 103(a) rejection based on Safar et al. in view of Coustou et al., Glover et al., or Wickner et al. Therefore, there is no need for teaching or suggestion from Safar et al. to combine the teachings of Coustou et al., Glover et al., or Wickner et al.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 3 and 5-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over Safar et al. (1993) in view of Coustou et al. (PNAS, 1997), Glover et al. (Cell, 1997; IDS reference) or Wickner (Science, 1994).

Safar et al. teach a detection of inactivation scrapie prion protein (PrP27-30), which is an analog as well as a fragment of a prion protein (biochemical indicator: claims 6 and 7) in a Petri dish (glass: claim 12) after treatment with proteinase K (protease/enzyme; chemical exposure: claims 9 and 10, see Results) or SDS (alkyl-group containing detergent; claims 9 and 10; see Fig.1) for inactivation (see Materials and Methods). Safar et al. also teach the detection was performed by Western blotting analysis (immuno-enzymatic method; claim 8: see Fig. 1).

Safar et al. do not teach the use of Sup35p, Ure2p or Het-s protein as an indicator.

Coustou et al. teach Het-s protein from *Podospora anserina* as an analog of a prion (see whole document).

Glover et al. teach Sup35p in *Saccharomyces cerevisiae* as a Yeast prion (see whole document). Glover et al. also teach an N-terminal fragment of Sup35p (residue 1-123) and a fragment NM comprising residues 1-253 (thus first 759bp of SUP35) of Sup35p (see Fig. 1), as well as a full-length Sup35p.

Wickner teaches the product of a chromosomal mutation in URE2 gene, called [URE3] is a prion form of Ure2p (see whole document).

It would therefore have been obvious for the person of ordinary skill in the art at the time the invention was made to use one of yeast prion analogs of Ure2p, Sup35p and Het-s protein taught by Wickner, Glover et al., and Coustou et al., respectively. This is because a person of ordinary skill in the art would recognize that the yeast prion

analogs have the same property as mammalian prion proteins, and thus suitable for replace the mammalian prion proteins as an indicator.

M.P.E.P. §2144.07 states "The selection of a known material based on its suitability for its intended use supported a prima facie obviousness determination in *Sinclair & Carroll Co. v. Interchemical Corp.*, 325 U.S. 327, 65 USPQ 297 (1945) (Claims to a printing ink comprising a solvent having the vapor pressure characteristics of butyl carbitol so that the ink would not dry at room temperature but would dry quickly upon heating were held invalid over a reference teaching a printing ink made with a different solvent that was nonvolatile at room temperature but highly volatile when heated in view of an article which taught the desired boiling point and vapor pressure characteristics of a solvent for printing inks and a catalog teaching the boiling point and vapor pressure characteristics of butyl carbitol. "Reading a list and selecting a known compound to meet known requirements is no more ingenious than selecting the last piece to put in the last opening in a jig-saw puzzle." 325 U.S. at 335, 65 USPQ at 301.)".

Although Safar et al. in view of Wickner, Glover et al., or Coustou et al. do not particularly teach the amount of indicator being 0.1 ng to 100 g, the reference teaches the amount of scrapie prions in molarity. Safar et al. teach that the amount of prion protein (PrP27-30) used in the method is 0.9 nmol in total 150 μ l of water, and the mean molecular weight of each residue is 109.5 (see page 2214; CD spectroscopy). Moreover, it is well known in the art and an inherent property of PrP27-30 to have about 142 amino acid residues supported by Prusiner (PNAS 1998, 95:13368-13383; see Fig. 2). Thus, a person of ordinary skill in the art can calculate the amount of PrP27-30 used

in the experiment, and it is about 140 μ g (claim 11).

With regard to the new limitation of "in amyloid form" in claim 3, the yeast analogs of mammalian prion as taught by Wickner, Glover et al., or Coustou et al. are considered all amyloid form because it is well known in the art that only those gene products of yeast in amyloid or amyloid-like form are considered as prion counterparts, and therefore a person of ordinary skill in the art would use an amyloid form of yeast prion analogs in place for the mammalian prion of Safar et al.

Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill at the time the invention was made.

Claim 9 is rejected under 35 U.S.C. 103(a) as being unpatentable over Safar et al. (supra) in view of Wickner, Glover et al., or Coustou et al. in further view of Feldman et al. (Compatibility of medical devices and materials with low-temperature hydrogen peroxide gas plasma, 1997).

Claim 9 is directed to limitations to sterilization process of claim 3 being performed by sterilization techniques using low temperature gas plasma or oxidizing sterilizing agents.

Safar et al. in view of Wickner, Glover et al., or Coustou et al. teach the limitation of claim 3 (see above).

Safar et al. in view of Wickner, Glover et al., or Coustou et al. do not teach the use of low temperature gas plasma or oxidizing sterilizing agents for

inactivation/sterilization process.

Feldman et al. teach the use of sterilization process to inactivate prion using oxidizing agents such as hydrogen peroxide as a form of low-temperature gas plasma (column 30, line 33 through column 34, line 42).

It would therefore have been obvious for the person of ordinary skill in the art at the time the invention was made to replace the inactivation/sterilization process in the method of Safar et al. in view of Wickner, Glover et al., or Coustou et al. with a sterilization technique of Feldman et al. using oxidizing sterilizing agents.

The skilled artisan would have been motivated to make such a modification because conventional sterilization techniques taught by Safar et al. have disadvantage such that high temperature may cause damage and safety concerns and steam also can corrode metal materials. However, the sterilization technique of Feldman et al. is safer and has no detrimental effects on containers made of various materials.

The person of ordinary skill in the art would have had a reasonable expectation of success in replacing sterilization technique of Safar et al. with that of Feldman et al. because such sterilization techniques of Feldman et al. is commercially available at the time of the invention made. For example, Sterrad system (Advanced Sterilization Products) using a sterilization technique of Feldman et al., which is commercially available.

Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill at the time the invention was made.

Claims 9, 10 and 13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Safar et al. (supra) in view of Wickner, Glover et al., or Coustou et al. in further view of Dresdner Jr. et al. (US 5,357,636).

Claims are directed to a limitation to sterilization process being performed by sterilization techniques using ozone-based exposure; a limitation to chemical exposure using sodium hydroxide; a limitation to a container being porous, permeable or semi-permeable.

Safar et al. in view of Wickner, Glover et al., or Coustou et al. teach the limitations of claim 3 (see above).

Safar et al. in view of Wickner, Glover et al., or Coustou et al. do not teach ozone-based exposure (claim 9), or sodium hydroxide as chemical exposure (claim 10).

Dresdner Jr. et al. teach the use of ozone (column 22, lines 44-52) or sodium hydroxide (column 27, line 48) as antiseptic composition.

It would therefore have been obvious for the person of ordinary skill in the art at the time the invention was made to use antiseptic compositions of Dresdner Jr. in the method of Safar et al. in view of Wickner, Glover et al., or Coustou et al. to test the efficacy of these sterilization techniques in elimination of prion proteins.

A person of ordinary skill in the art would recognize the use of ozone or sodium hydroxide of Dresdner Jr. et al. as an art-recognized equivalent to the sterilization technique used by Safar et al. in view of Wickner, Glover et al., or Coustou et al.

M.P.E.P. §2144.06 states "In re Scott, 323 F.2d 1016, 139 USPQ 297 (CCPA

1963) (Claims were drawn to a hollow fiberglass shaft for archery and a process for the production thereof where the shaft differed from the prior art in the use of a paper tube as the core of the shaft as compared with the light wood or hardened foamed resin core of the prior art. The Board found the claimed invention would have been obvious, reasoning that the prior art foam core is the functional and mechanical equivalent of the claimed paper core. The court reversed, holding that components which are functionally or mechanically equivalent are not necessarily obvious in view of one another, and in this case, the use of a light wood or hardened foam resin core does not fairly suggest the use of a paper core.); *Smith v. Hayashi*, 209 USPQ 754 (Bd. of Pat. Inter. 1980) (The mere fact that phthalocyanine and selenium function as equivalent photoconductors in the claimed environment was not sufficient to establish that one would have been obvious over the other. However, there was evidence that both phthalocyanine and selenium were known photoconductors in the art of electrophotography. "This, in our view, presents strong evidence of obviousness in substituting one for the other in an electrophotographic environment as a photoconductor." 209 USPQ at 759.)."

Safar et al. in view of Wickner, Glover et al., or Coustou et al. do not teach the container being porous, permeable or semi-permeable.

Dresdner Jr. et al. also teach a porous and liquid-permeable medical glove for sterilization process (column 18, line 40; column 23, line 56).

It would therefore have been obvious for the person of ordinary skill in the art at the time the invention was made to replace a glass container of Safar et al. with a

medical glove of Dresdner Jr. et al.

The skilled artisan would have been motivated to make such a modification because contamination of prion proteins can happen in various different materials such as plastics, metal, or polymer, sterilization process should be carried out in various materials. Moreover, medical gloves are routinely used in hospitals and laboratories and are subject to prion contamination. Therefore, medical gloves of Dresdner Jr. et al. can be used in place of a glass container of Safar et al. to determine effectiveness of various prion sterilization techniques without damaging the material containing a prion protein.

The person of ordinary skill in the art would have had a reasonable expectation of success in replacing a glass container of Safar et al. with a medical glove of Dresdner Jr. et al. because medical gloves used in hospitals and laboratories are subject to routine sterilization to decontaminate pathogens such as prion.

Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill at the time the invention was made.

Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not

Art Unit: 1651

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taeyoon Kim whose telephone number is (571)272-9041. The examiner can normally be reached on 8:00 am - 4:00 pm ET (Mon-Thu).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn can be reached on 571-272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Leon B Lankford Jr/
Primary Examiner, Art Unit 1651

Taeyoon Kim
AU-1651